Xilio Therapeutics (XLO) Set for Triple-Digit Revenue Growth in Q2 2025 Earnings Preview

WALTHAM, MA – All eyes are on Xilio Therapeutics Inc. (XLO) as the company prepares to release its second-quarter financial results for the period ending June 30, 2025. The report, with an estimated release date of August 6, is highly anticipated, as current forecasts point to a dramatic increase in the company’s quarterly revenue.

A Surge in Revenue Expected

According to the latest LSEG data, Xilio Therapeutics is expected to post a significant top-line improvement. The current consensus estimate, based on the forecast from one analyst, projects quarterly revenue to reach $7.4 million.

This figure represents a staggering 214.0% increase compared to the $2.36 million in revenue reported during the same period in the previous year. Such a substantial year-over-year jump suggests a potentially transformative quarter for the Waltham-based biotechnology company.

The Bottom-Line and Analyst Sentiment

While the revenue forecast is a key point of interest, investors will also be closely watching the company’s profitability. LSEG’s mean analyst estimate for Xilio Therapeutics indicates an expected loss of 10 cents per share for the quarter.

Despite the projected loss, the current Wall Street outlook on the company’s stock appears positive. Key points on analyst sentiment include:

• Analyst Rating: The one available analyst rating on XLO shares is a “Buy”, signaling confidence in the stock’s potential.

• Estimate Stability: The mean earnings estimate from analysts has remained unchanged over the past three months, suggesting a stable and consistent outlook leading into the earnings announcement.

Investors and market watchers will be looking for confirmation of this strong revenue growth on August 6 and will be keen to hear any management commentary on the company’s performance and future outlook.